J Korean Soc Osteoporos.  2010 Apr;8(1):56-63.

Bone Mineral Density and Bone Turnover Markers after One-year Teriparatide Treatment in Korean Postmenopausal Women with Osteoporosis

• Park SY
• Bae JH
• Kim JY
• Oh HJ
• Joo IW

Abstract

OBJECTIVES
Recombinant teriparatide, a bone anabolic agent, is known to result in a net positive bone balance and reduce vertebral and nonvertebral fracture incidence. The objective of this study was to evaluate the changes of bone mineral density (BMD) and bone turnover markers after one-year teriparatide treatment in Korean postmenopausal women with osteoporosis.
METHODS
The enrolled postmenopausal women with osteoporosis were administered teriparatide 20microg/day injection for one year. BMD at the lumber spine and the hip were measured at baseline and after one year by dual-energy X-ray absorptiometry. Also, serum bone turnover markers, such as osteocalcin, C-telopeptide of collagen cross-links (CTX), and alkaline phosphatase were measured at baseline and after one year.
RESULTS
Lumbar spine BMD increased from baseline (4.4%, P<0.01), but femoral neck BMD decreased from baseline (-9.7%, P<0.05). Bone turnover markers, such as osteocalcin (148.5%), CTX (67.6%), and alkaline phosphatase (56.7%) increased from baseline (P<0.001 for all).
CONCLUSION
One year of teriparatide treatment significantly increased lumbar spine BMD and bone turnover markers in Korean postmenopausal women with osteoporosis. The large-populated prospective study with longer administered period will be needed in the future.

Keyword

Osteoporosis; Teriparatide; Bone mineral density; Bone turnover marker; ostmenopausal women

MeSH Terms

Absorptiometry, Photon
Alkaline Phosphatase
Bone Density
Collagen
Collagen Type I
Female
Femur Neck
Hip
Humans
Incidence
Osteocalcin
Osteoporosis
Peptides
Spine
Teriparatide
Alkaline Phosphatase
Collagen
Collagen Type I
Osteocalcin
Peptides
Teriparatide